Aduhelm Overkill: Broad Medicare Policy Is Unreasonable – And Unnecessary

The US Centers for Medicare & Medicaid Services is taking a remarkable stance in its final coverage policy on beta amyloid targeted Alzheimer’s therapy.

The agency is asserting that its coverage standard – whether a drug is “reasonable and necessary” for the Medicare population – would not be met by a product that received a traditional approval (i.e